CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08 janv. 2025 08h30 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
07 janv. 2025 08h00 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
09 déc. 2024 12h00 HE
|
CRISPR Therapeutics AG
-Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol- -Company announced...
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
14 nov. 2024 08h30 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
07 nov. 2024 08h00 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
05 nov. 2024 09h01 HE
|
CRISPR Therapeutics AG
-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized...
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
05 août 2024 16h01 HE
|
CRISPR Therapeutics AG
-More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July- -Clinical trials...
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
29 mai 2024 08h00 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
23 mai 2024 08h00 HE
|
CRISPR Therapeutics AG
-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) --...
CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
09 mai 2024 08h30 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...